45 - References

References

Bipolar disorder CHAPTER 2 References

1. Keramatian K, et al. Long-­acting injectable second-­generation/atypical antipsychotics for the management of bipolar disorder: a systematic review. CNS Drugs 2019; 33:431–­456.
2. Pacchiarotti I, et al. Long-­acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychopharmacol 2019; 29:457–­470.
3. Prajapati AR, et al. Second-­generation antipsychotic long-­acting injections in bipolar disorder: systematic review and meta-­analysis. Bipolar Disord 2018; 20:687–­696.
4. Goto J, et al. Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: a multicenter 1-­year retrospective mirror image study. Neuropsychopharmacol Rep 2023; 43:425–­433.
5. Woo YS, et al. Preventive effect of aripiprazole once-­monthly on relapse into mood episodes in bipolar disorder: a multicenter, one-­year, retrospective, mirror image study. J Affect Disord 2024; 351:381–­386.
6. Yıldızhan E, et al. Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder –­ a naturalistic mirror image study. Nord J Psychiatry 2022; 76:37–­43.
7. Caliskan AM, et al. Impact of initiating long-­acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: a mirror image retrospective study. Asian J Psychiatr 2020; 54:102457.
8. Harlin M, et al. A randomized, open-­label, multiple-­dose, parallel-­arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-­month long-­acting injectable in adults with schizophrenia or bipolar I disorder. CNS Drugs 2023; 37:337–­350.
9. McIntyre RS, et al. Safety and efficacy of aripiprazole 2-­month ready-­to-­use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-­label, parallel-­arm, pivotal study. Curr Med Res Opin 2023; 39:1021–­1030.
10. Esparon J, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-­depressive patients. Br J Psychiatry 1986; 148:723–­725.
11. Yatham L, et al. Randomised trial of oral vs. injectable antipsychotics in bipolar disorder. Presented at the 6th International Conference on Bipolar Disorder: 16–18 June 2005, Pittsburgh, PA.
12. Ahlfors UG, et al. Flupenthixol decanoate in recurrent manic-­depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981; 64:226–­237.
13. Macfadden W, et al. A randomized, double-­blind, placebo-­controlled study of maintenance treatment with adjunctive risperidone long-­acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009; 11:827–­839.
14. Quiroz JA, et al. Risperidone long-­acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68:156–­162.
15. Vieta E, et al. A randomized, double-­blind, placebo-­controlled trial to assess prevention of mood episodes with risperidone long-­acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012; 22:825–­835.
16. Calabrese JR, et al. Efficacy and safety of aripiprazole once-­monthly in the maintenance treatment of bipolar I disorder: a double-­blind, placebo-­controlled, 52-­week randomized withdrawal study. J Clin Psychiatry 2017; 78:324–­331.
17. Calabrese JR, et al. Aripiprazole once-­monthly as maintenance treatment for bipolar I disorder: a 52-­week, multicenter, open-­label study. Int J Bipolar Disord 2018; 6:14.
18. Berwaerts J, et al. A randomized, placebo-­ and active-­controlled study of paliperidone extended-­release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012; 138:247–­258.
19. Buoli M, et al. Paliperidone palmitate depot in the long-­term treatment of psychotic bipolar disorder: a case series. Clin Neuropharmacol 2015; 38:209–­211.
20. Li K, et al. Case report: paliperidone palmitate in the management of bipolar I disorder with non-­compliance. Front Psychiatry 2020; 11:529672.
21. Bond DJ, et  al. Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr Scand Suppl 2007; 2007:3–­16.
22. Gigante AD, et al. Long-­acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs 2012; 26:403–­420.
23. Goikolea JM, et al. Lower rate of depressive switch following antimanic treatment with second-­generation antipsychotics versus haloperidol. J Affect Disord 2013; 144:191–­198.
24. Wu CS, et al. Comparative effectiveness of long-­acting injectable risperidone vs. long-­acting injectable first-­generation antipsychotics in bipolar disorder. J Affect Disord 2016; 197:189–­195.
25. Bartoli F, et al. Effect of long-­acting injectable antipsychotics on 1-­year hospitalization in bipolar disorder: a mirror-­image study. Eur Arch Psychiatry Clin Neurosci 2023; 273:1579–­1586.